Market Closed -
Nasdaq
16:00:00 2024-05-08 EDT
|
5-day change
|
1st Jan Change
|
9.81
USD
|
-5.13%
|
|
+0.93%
|
+30.31%
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
744.1
|
1,057
|
172.7
|
57.79
|
76.05
|
203.6
|
-
|
-
|
Enterprise Value (EV)
1 |
578
|
626.9
|
-132.4
|
-127.8
|
-20.47
|
54.86
|
68.08
|
203.6
|
P/E ratio
|
-11.4
x
|
-7.86
x
|
-1.19
x
|
-0.37
x
|
-0.65
x
|
-1.79
x
|
-1.83
x
|
-1.8
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
2,976
x
|
-
|
23
x
|
-
|
21.1
x
|
648
x
|
23
x
|
16.4
x
|
EV / Revenue
|
2,312
x
|
-
|
-17.7
x
|
-
|
-5.69
x
|
175
x
|
7.68
x
|
16.4
x
|
EV / EBITDA
|
-8.63
x
|
-5.51
x
|
0.94
x
|
0.85
x
|
0.17
x
|
-0.49
x
|
-0.45
x
|
-1.28
x
|
EV / FCF
|
-8.45
x
|
-6.88
x
|
1.08
x
|
1.07
x
|
0.22
x
|
-0.57
x
|
-0.89
x
|
-1.17
x
|
FCF Yield
|
-11.8%
|
-14.5%
|
92.8%
|
93.8%
|
448%
|
-175%
|
-113%
|
-85.2%
|
Price to Book
|
4.22
x
|
2.12
x
|
0.55
x
|
0.32
x
|
0.91
x
|
1.56
x
|
1.92
x
|
-
|
Nbr of stocks (in thousands)
|
6,459
|
9,748
|
9,815
|
9,973
|
10,103
|
20,755
|
-
|
-
|
Reference price
2 |
115.2
|
108.4
|
17.60
|
5.795
|
7.528
|
9.810
|
9.810
|
9.810
|
Announcement Date
|
20-03-12
|
21-03-01
|
22-03-29
|
23-03-30
|
24-03-18
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
0.25
|
-
|
7.5
|
-
|
3.6
|
0.3143
|
8.87
|
12.4
|
EBITDA
1 |
-66.97
|
-113.8
|
-141.5
|
-150.6
|
-118.3
|
-111
|
-151
|
-159
|
EBIT
1 |
-68.54
|
-118
|
-146.1
|
-157.1
|
-124
|
-119.1
|
-143.1
|
-169.3
|
Operating Margin
|
-27,418%
|
-
|
-1,948.29%
|
-
|
-3,444.19%
|
-37,888.95%
|
-1,612.84%
|
-1,365.42%
|
Earnings before Tax (EBT)
1 |
-64.49
|
-116.4
|
-145.5
|
-154.5
|
-118.2
|
-116.1
|
-137.9
|
-169.4
|
Net income
1 |
-64.49
|
-117.5
|
-145.5
|
-154.5
|
-117.2
|
-114.8
|
-139.6
|
-166.9
|
Net margin
|
-25,794.4%
|
-
|
-1,940.53%
|
-
|
-3,254.58%
|
-36,517.81%
|
-1,573.69%
|
-1,346.32%
|
EPS
2 |
-10.10
|
-13.80
|
-14.80
|
-15.60
|
-11.60
|
-5.496
|
-5.364
|
-5.464
|
Free Cash Flow
1 |
-68.42
|
-91.14
|
-123
|
-119.9
|
-91.71
|
-96.21
|
-76.78
|
-173.6
|
FCF margin
|
-27,366.8%
|
-
|
-1,639.39%
|
-
|
-2,547.5%
|
-30,611.32%
|
-865.65%
|
-1,399.93%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
20-03-12
|
21-03-01
|
22-03-29
|
23-03-30
|
24-03-18
|
-
|
-
|
-
|
Fiscal Period: December |
2021 Q3
|
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
2025 Q1
|
---|
Net sales
1 |
-
|
-
|
-
|
-
|
-
|
-
|
3.6
|
-
|
-
|
-
|
0.0729
|
0.0766
|
0.0803
|
0.0846
|
-
|
EBITDA
1 |
-37.56
|
-33.1
|
-36.71
|
-42.42
|
-39.25
|
-32.23
|
-28.65
|
-31.53
|
-33.02
|
-25.15
|
-27
|
-27
|
-28
|
-29
|
-34
|
EBIT
1 |
-38.52
|
-34.42
|
-38.13
|
-44.02
|
-41.04
|
-33.94
|
-30.24
|
-33.06
|
-34.53
|
-26.16
|
-27.78
|
-28.94
|
-30.37
|
-32
|
-33.88
|
Operating Margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-839.97%
|
-
|
-
|
-
|
-38,133.86%
|
-37,792.87%
|
-37,829.12%
|
-37,841.43%
|
-
|
Earnings before Tax (EBT)
1 |
-38.36
|
-34.41
|
-37.89
|
-43.74
|
-40.11
|
-32.72
|
-29.04
|
-31.49
|
-32.87
|
-24.85
|
-27.12
|
-28.08
|
-29.66
|
-31.25
|
-31.5
|
Net income
1 |
-38.36
|
-34.41
|
-37.91
|
-43.76
|
-40.13
|
-32.74
|
-29.06
|
-31.51
|
-32.88
|
-23.71
|
-26.89
|
-27.85
|
-29.34
|
-30.67
|
-32.62
|
Net margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-807.11%
|
-
|
-
|
-
|
-36,910.06%
|
-36,378.26%
|
-36,542.75%
|
-36,263.84%
|
-
|
EPS
2 |
-3.900
|
-3.500
|
-3.800
|
-4.400
|
-4.000
|
-3.300
|
-2.900
|
-3.100
|
-3.300
|
-2.300
|
-1.411
|
-1.344
|
-1.367
|
-1.400
|
-1.550
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
21-11-04
|
22-03-29
|
22-05-12
|
22-08-11
|
22-11-10
|
23-03-30
|
23-05-11
|
23-08-10
|
23-11-09
|
24-03-18
|
-
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
1 |
166
|
430
|
305
|
186
|
96.5
|
149
|
136
|
-
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
-68.4
|
-91.1
|
-123
|
-120
|
-91.7
|
-96.2
|
-76.8
|
-174
|
ROE (net income / shareholders' equity)
|
-
|
-38.6%
|
-
|
-
|
-
|
-
|
-
|
-
|
ROA (Net income/ Total Assets)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Assets
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Book Value Per Share
2 |
27.30
|
51.00
|
32.30
|
18.10
|
8.280
|
6.300
|
5.100
|
-
|
Cash Flow per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capex
1 |
19.2
|
11.8
|
15.1
|
11.8
|
0.81
|
0.81
|
0.74
|
0.72
|
Capex / Sales
|
7,698.8%
|
-
|
201.64%
|
-
|
22.44%
|
257.09%
|
8.36%
|
5.78%
|
Announcement Date
|
20-03-12
|
21-03-01
|
22-03-29
|
23-03-30
|
24-03-18
|
-
|
-
|
-
|
Last Close Price
10.34
USD Average target price
35.33
USD Spread / Average Target +241.71% Consensus |
1st Jan change
|
Capi.
|
---|
| +30.31% | 215M | | +2.93% | 106B | | +7.02% | 23.47B | | -14.60% | 21.9B | | -7.05% | 18.77B | | -38.55% | 17.85B | | -8.83% | 16.78B | | +5.51% | 14.41B | | +37.49% | 12.86B | | +329.39% | 8.78B |
Bio Therapeutic Drugs
|